Business
Profound to Showcase TULSA-PRO®, the TULSA Procedure(TM) and the Future of iMRI at AUA2026
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) --   Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (...
About this update from Profound Medical Corp
[{"type":"text","content":"Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026Company to explore the potential of integrating TULSA-PRO with PSMA PET molecular imaging technologies to enhance ablation planning and monitoring\nTORONTO, May 14, 2026 (GLOBE NEWSWIRE) --  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is pleased to announce that the TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association’s (“AUA”) Annual Meeting in Washington, DC, in the session titled “Prostate Cancer: Localized: Ablative Therapy II” on May 16th from 1:00-3:00 p.m. ET. TULSA Procedure Talks at AUA2026 Ram A. Pathak, M.D., Associate Professor in the Department of Urology at Mayo Clinic in Florida, will give a presentation titled \"Multicenter registry of MRI-guided transurethral ultrasound ablation (TULSA): MRI characteristics associated with treatment outcome\";Mikael Anttinen, M.D., Ph.D., a Urologist at Turku University Hospital in Finland, will give a presentation titled \"Morphologic and perfusion changes induced by short-term neoadjuvant and androgen deprivation therapy before MRI-guided transurethral ultrasound ablation for localized prostate cancer\";Dr. Anttinen will also give a presentation titled: “Lesion-targeted MRI-guided transurethral ultrasound ablation for localized prostate cancer: 12-month safety, efficacy, and functional outcomes from a phase 2 trial”; andMasayoshi Miura, M.D., Ph.D., the Director of the Department of Urology and Renal Transplantation Surgery at Sapporo Hokuyu Hospital in Japan, will give a presentation titled “Transurethral ultrasound ablation of the prostate is effective for localized prostate cancer and functional preservation: Single-center real world data”. A Complete Interventional MRI (“iMRI”) Solution for Prostate Ablation To see the future of iMRI prostate ablation first-hand, Profound is pleased to invite AUA2026 attendees to visit Booth #413, where it will host demonstrations of TULSA-PRO® and display an actual Siemens MAGNETOM Free.Max MR.1 The P...